Pay in 4 interest-free payments of $5.12 Learn more
Ships within 48 hours · Estimated delivery Aug 25 - Aug 30
Retatrutide (Triple Agonist) Retatrutide, developed by Eli Lilly, is a "triple agonist" that targets GLP-1, GIP, and glucagon receptors
It was specifically engineered to isolate the fat-regulating portion of the growth hormone molecule without activating the pathways that affect IGF-1, insulin, or blood sugar
:max_bytes(150000):strip_icc()/VWH-GettyImages-2178836417-ee318a41780b44e9af3ff47de83fafd7.jpg)
sometimes I crave something sweet without all the guilt
These mechanistic interactions are supported by preclinical and early-phase human data, and their relative contributions in clinical practice continue to be studied
US$ 28.44
US$ 25.26
US$ 26.22
US$ 25.87
US$ 26.40
US$ 21.38
US$ 20.24
US$ 27.25
US$ 28.08
US$ 24.59
